Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato) titanium(IV) compounds against Walker 256 carcinosarcoma. A new class of antineoplastic agents
- PMID: 6890355
Item in Clipboard
Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato) titanium(IV) compounds against Walker 256 carcinosarcoma. A new class of antineoplastic agents
Arzneimittelforschung.
1982.
Abstract
The antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium(IV) compounds against Walker 256 carcinosarcoma in comparison to cis-dichlorodiammineplatinum(II) (cisplatin, cis-DDP, NSC 119875) was investigated. The tested compounds showed in this experimental model an enhanced median survival time and a lower toxicity compared to cisplatin.
Similar articles
-
Antitumor activity of phenyl substituted dihalogenobis (1-phenyl-1,3-butanedionato)titanium (IV) compounds.Arzneimittelforschung. 1985;35(12):1832-6. Arzneimittelforschung. 1985. PMID: 4096739
-
Preclinical evaluation of diethoxy-(1-phenyl-1,3-butanedionato) titanium (IV) in human tumour xenografts.Arzneimittelforschung. 1984;34(10):1289-90. Arzneimittelforschung. 1984. PMID: 6549134
-
Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium (IV) compounds. A new class of antineoplastic agents.J Cancer Res Clin Oncol. 1983;105(1):109-10. doi: 10.1007/BF00391842. J Cancer Res Clin Oncol. 1983. PMID: 6682104 Free PMC article.
-
Organometallic compounds in oncology: implications of novel organotins as antitumor agents.Drug Discov Today. 2009 May;14(9-10):500-8. doi: 10.1016/j.drudis.2009.02.002. Epub 2009 Feb 11. Drug Discov Today. 2009. PMID: 19429510 Review.
-
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.Drug Resist Updat. 2006 Jun;9(3):111-22. doi: 10.1016/j.drup.2006.05.002. Epub 2006 Jun 21. Drug Resist Updat. 2006. PMID: 16790363 Review.
Cited by
-
Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats.Cancer Chemother Pharmacol. 1987;19(4):347-9. doi: 10.1007/BF00261487. Cancer Chemother Pharmacol. 1987. PMID: 2954714
-
Metal-Organic Frameworks for Cisplatin Delivery to Cancer Cells: A Molecular Dynamics Simulation.ACS Omega. 2024 Apr 22;9(17):19627-19636. doi: 10.1021/acsomega.4c01437. eCollection 2024 Apr 30. ACS Omega. 2024. PMID: 38708264 Free PMC article.
-
Ionic titanocene complexes: a new type of antitumor agent.Cancer Chemother Pharmacol. 1989;24(1):23-7. doi: 10.1007/BF00254100. Cancer Chemother Pharmacol. 1989. PMID: 2720888
-
Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane.Invest New Drugs. 1996;13(4):327-32. doi: 10.1007/BF00873139. Invest New Drugs. 1996. PMID: 8824351 Clinical Trial.
-
Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats.J Cancer Res Clin Oncol. 1992;118(3):195-200. doi: 10.1007/BF01410134. J Cancer Res Clin Oncol. 1992. PMID: 1548284 Free PMC article.